BUCHANG PHARMA(SH:603858) Mei Ri Jing Ji Xin Wen·2025-06-11 13:51Group 1 - The core initiative "Together, Building China's Heart" has been active for 18 years, providing medical assistance to over 1 million people across various regions, particularly focusing on congenital heart disease [1][3][4] - The program has mobilized over 32,000 medical experts from more than 3,000 medical institutions, expanding its services from congenital heart disease to multiple medical specialties [3][4] - The initiative has successfully completed over 3,000 surgeries for children with congenital heart disease and conducted more than 3,000 health education activities [4] Group 2 - The "1+1 Employee Relief Fund" was established in 2009 to support employees in need, with a total donation of 8.526 million yuan and 8.335 million yuan used for relief [6][7] - The fund not only assists employees but also extends support to their families, demonstrating the company's commitment to employee welfare [7] - The fund has positively influenced company culture, fostering a sense of community and responsibility among employees [7] Group 3 - The company emphasizes the integration of social responsibility with business operations, maintaining a strong commitment to innovation and shareholder returns [9][10] - Since its listing in 2016, the company has paid out 9.183 billion yuan in cash dividends and buybacks, exceeding the raised capital [9] - The company has contributed nearly 32 billion yuan in taxes since its establishment, highlighting its role in supporting local economic development [9] Group 4 - The company is actively involved in research and development, focusing on innovative drugs and high-quality generics, while also expanding its international presence [10] - The company's philosophy of "altruism" is seen as complementary to profitability, enhancing its social reputation and employee loyalty [10]